- Home
- PSFE vs NTLA Comparison
PSFE vs NTLA Comparison
Compare PSFE & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSFE
- NTLA
- Stock Information
- Founded
- PSFE 1996
- NTLA 2014
- Country
- PSFE United Kingdom
- NTLA United States
- Employees
- PSFE N/A
- NTLA N/A
- Industry
- PSFE Business Services
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PSFE Consumer Discretionary
- NTLA Health Care
- Exchange
- PSFE Nasdaq
- NTLA Nasdaq
- Market Cap
- PSFE 1.4B
- NTLA 1.4B
- IPO Year
- PSFE N/A
- NTLA 2016
- Fundamental
- Price
- PSFE $17.29
- NTLA $12.18
- Analyst Decision
- PSFE Hold
- NTLA Buy
- Analyst Count
- PSFE 5
- NTLA 17
- Target Price
- PSFE $19.40
- NTLA $56.63
- AVG Volume (30 Days)
- PSFE 381.8K
- NTLA 2.4M
- Earning Date
- PSFE 11-13-2024
- NTLA 02-20-2025
- Dividend Yield
- PSFE N/A
- NTLA N/A
- EPS Growth
- PSFE N/A
- NTLA N/A
- EPS
- PSFE N/A
- NTLA N/A
- Revenue
- PSFE $1,699,306,000.00
- NTLA $43,086,000.00
- Revenue This Year
- PSFE $9.73
- NTLA $52.50
- Revenue Next Year
- PSFE $7.00
- NTLA $0.42
- P/E Ratio
- PSFE N/A
- NTLA N/A
- Revenue Growth
- PSFE 8.22
- NTLA N/A
- 52 Week Low
- PSFE $11.89
- NTLA $11.79
- 52 Week High
- PSFE $26.25
- NTLA $34.87
- Technical
- Relative Strength Index (RSI)
- PSFE 34.48
- NTLA 34.42
- Support Level
- PSFE $16.84
- NTLA $11.79
- Resistance Level
- PSFE $18.48
- NTLA $13.79
- Average True Range (ATR)
- PSFE 0.69
- NTLA 0.85
- MACD
- PSFE -0.15
- NTLA -0.14
- Stochastic Oscillator
- PSFE 12.59
- NTLA 9.97
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet, and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.